Abstract 303P
Background
Mandibulectomy typically involves rigid reconstruction using autologous bone and titanium plates. However, in cases with poor performance status or complications as well as the elderly, choosing the optimal surgical method is difficult. For such cases in our hospital, we do not perform rigid reconstruction but opt for only soft tissue reconstruction or primary suturing at the defect site. Here, we retrospectively investigated cases where primary suturing was applied and discuss the utility of the procedure.
Methods
This retrospective study targeted cases of stage T4 lower gingival carcinoma treated with segmental mandibulectomy and primary suturing at the defect site between 1992 and 2018. Survey items were operative time, blood loss volume, perioperative complications, length of hospitalization, and food intake at discharge.
Results
There were 186 cases for which segmental mandibulectomy was performed during the target period, and 13 cases for which primary suturing was also performed. Median operative time was 210 (range, 124-328) min. Median blood loss was 212 (101-867) mL. Six cases had complications during the perioperative period, but in all cases cure was achieved by conservative treatment. Median length of hospitalization was 32 (20-49) days. All cases could tolerate oral intake at discharge.
Conclusions
Segmental mandibulectomy without reconstruction may be a viable surgical option for cases where free tissue reconstruction is not possible.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract